Background And Objectives: INTERCEPT Blood System™ is a pathogen inactivation system for blood components. The initial approval required a platelet component to be suspended in a combination of plasma and Platelet additive Solution/PAS-III. Improved platelet storage has been reported with Mg++ and K+ supplementation (PAS-IIIM). This study validated the use of INTERCEPT™/PAS-IIIM for apheresis and pooled buffy-coat platelet components.
Materials And Methods: The platelet dose and pH throughout 5 days of storage met the European and French requirements for quality standards.
Results And Conclusion: Additional metabolic and activation assessments of the treated platelets confirmed the previously reported superiority of PAS-IIIM over PAS-III, but extended it to the INTERCEPT™ process.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1423-0410.2010.01389.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Apheresis in the Remission of Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-Analysis.
Clin Ther
January 2025
CarVasCare Research Group (2023-GRIN-34459), Faculty of Nursing, Universidad de Castilla-La Mancha, Cuenca, Spain.
Purpose: Sudden sensorineural hearing loss (SSHL) is an abrupt hearing loss, often of unknown cause. Apheresis is a treatment option aimed at improving blood hemorheology by removing pathogenic blood components. There are currently no previous meta-analyses on its efficacy.
View Article and Find Full Text PDFTumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.
Nat Commun
January 2025
Center for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we developed a high-throughput microfluidic device, depleting hematopoietic cells through high-flow channels and force-amplifying magnetic lenses. Here, we apply this technology to analyze patient-derived leukapheresis products, interrogating a mean blood volume of 5.
View Article and Find Full Text PDFEffects of multiple apheresis platelet donations for the iron nutrition condition and platelet parameters of blood donors in China: A meta-analysis study.
Transfus Apher Sci
December 2024
Blood Donation Service Section I, Huzhou Central Blood Station, Huzhou 313000, China.
Background: Apheresis platelets is a common platelets collection method with high purity and relatively few adverse reactions. This study aimed to explore the effects of multiple apheresis platelet donations on the condition of iron nutrition and platelet parameters of donors in China.
Methods: Eligible studies were selected from PubMed, EMBASE, Wanfang, CQVIP, and the Chinese National Knowledge Infrastructure (CNKI) databases.
Purified Granulocyte Concentrates from Buffy Coats with Extended Storage Time.
Transfus Med Hemother
December 2024
Artcline GmbH, Rostock, Germany.
Article Synopsis
- Granulocyte concentrates (GCs) can be made from pooled buffy coats of whole blood donations, allowing for better availability and longer storage times compared to those made from single-donor apheresis, which can only last 24 hours.
- A process was developed to significantly reduce red blood cell and platelet contamination, extending the shelf life of GCs up to 72 hours while maintaining high cell viability (above 98%) and functionality (with over 95% rates of phagocytosis and oxidative burst).
- To produce a therapeutic dose of GCs, around 15-20 buffy coats are needed, offering a more efficient alternative for treatment compared to traditional methods.
GRAIN Study - Granulocytes Against Infections - Use of granulocyte transfusion in haematopoietic stem cell transplant.
Transfus Apher Sci
December 2024
Department of Clinical Haematology, Christian Medical College, Vellore, India. Electronic address:
Granulocyte transfusions (GTx) combat infections in neutropenic patients. However, immune-mediated off-target effects in transplant settings are unknown. Between January 2020 and December 2021, all transplants that used GTx during the peri-transplant period were analysed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!